RU2005129278A - Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз - Google Patents
Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз Download PDFInfo
- Publication number
- RU2005129278A RU2005129278A RU2005129278/14A RU2005129278A RU2005129278A RU 2005129278 A RU2005129278 A RU 2005129278A RU 2005129278/14 A RU2005129278/14 A RU 2005129278/14A RU 2005129278 A RU2005129278 A RU 2005129278A RU 2005129278 A RU2005129278 A RU 2005129278A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- acetate
- concentration
- glucocorticoid
- fluoromethalone
- Prior art date
Links
- 239000003862 glucocorticoid Substances 0.000 title claims 7
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000001575 pathological effect Effects 0.000 title 1
- 229940037128 systemic glucocorticoids Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 7
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 4
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 4
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229960002800 prednisolone acetate Drugs 0.000 claims 3
- 229960001487 rimexolone Drugs 0.000 claims 2
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- -1 romexolone Chemical compound 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44894403P | 2003-02-20 | 2003-02-20 | |
| US60/448,944 | 2003-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005129278A true RU2005129278A (ru) | 2006-01-27 |
Family
ID=32908675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005129278/14A RU2005129278A (ru) | 2003-02-20 | 2004-02-05 | Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20060074061A1 (https=) |
| EP (1) | EP1594511A2 (https=) |
| JP (2) | JP2006518383A (https=) |
| KR (1) | KR20050102653A (https=) |
| CN (1) | CN100431544C (https=) |
| AR (1) | AR043252A1 (https=) |
| AU (1) | AU2004212900A1 (https=) |
| BR (1) | BRPI0407742A (https=) |
| CA (1) | CA2516790A1 (https=) |
| MX (1) | MXPA05008396A (https=) |
| PL (1) | PL378209A1 (https=) |
| RU (1) | RU2005129278A (https=) |
| TW (1) | TW200507858A (https=) |
| UY (1) | UY28203A1 (https=) |
| WO (1) | WO2004073608A2 (https=) |
| ZA (1) | ZA200505990B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006113593A (ru) * | 2003-09-23 | 2006-08-27 | Алькон, Инк. (Ch) | Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций |
| US7257366B2 (en) * | 2003-11-26 | 2007-08-14 | Osmosis Llc | System and method for teaching a new language |
| US9693967B2 (en) | 2005-09-07 | 2017-07-04 | Southwest Research Institute | Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates |
| BRPI0615563A2 (pt) * | 2005-09-07 | 2011-05-24 | Southwest Res Inst | formulações farmacêuticas em micropartìcula biodegradável exibindo taxas de liberação aperfeiçoadas |
| KR20080087814A (ko) * | 2005-12-22 | 2008-10-01 | 알콘 리서치, 리미티드 | 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제 |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| GB0625844D0 (en) * | 2006-12-22 | 2007-02-07 | Daniolabs Ltd | The treatment of macular degeneration |
| KR20100051811A (ko) * | 2007-07-20 | 2010-05-18 | 알콘, 인코퍼레이티드 | 눈에 수용체 티로신 키나제 저해(ｒｔｋｉ) 화합물을 전달하기 위한 약제학적 제제 |
| ES2566934T3 (es) * | 2010-05-10 | 2016-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina |
| WO2015191795A1 (en) * | 2014-06-12 | 2015-12-17 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
| US4686214A (en) * | 1985-10-30 | 1987-08-11 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5371078A (en) * | 1988-10-31 | 1994-12-06 | Alcon Laboratories, Inc. | Angiostatic steroids and methods and compositions for controlling ocular hypertension |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| AU684115B2 (en) * | 1993-12-27 | 1997-12-04 | Mitsubishi Chemical Corporation | Ophthalmic suspension containing diflupredonate |
| US5646136A (en) * | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
| US5516522A (en) * | 1994-03-14 | 1996-05-14 | Board Of Supervisors Of Louisiana State University | Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
| CA2383499C (en) * | 1999-10-21 | 2009-11-24 | Alcon Universal Ltd. | Drug delivery device |
| JP2003511204A (ja) * | 1999-10-21 | 2003-03-25 | アルコン，インコーポレイティド | テノン下薬剤送出 |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| ES2244361T1 (es) * | 2002-08-05 | 2005-12-16 | Alcon, Inc. | Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad. |
-
2004
- 2004-02-05 WO PCT/US2004/003515 patent/WO2004073608A2/en not_active Ceased
- 2004-02-05 ZA ZA200505990A patent/ZA200505990B/xx unknown
- 2004-02-05 CN CNB2004800043514A patent/CN100431544C/zh not_active Expired - Fee Related
- 2004-02-05 MX MXPA05008396A patent/MXPA05008396A/es unknown
- 2004-02-05 PL PL378209A patent/PL378209A1/pl unknown
- 2004-02-05 BR BRPI0407742-3A patent/BRPI0407742A/pt not_active IP Right Cessation
- 2004-02-05 AU AU2004212900A patent/AU2004212900A1/en not_active Abandoned
- 2004-02-05 CA CA002516790A patent/CA2516790A1/en not_active Abandoned
- 2004-02-05 RU RU2005129278/14A patent/RU2005129278A/ru not_active Application Discontinuation
- 2004-02-05 EP EP04708663A patent/EP1594511A2/en not_active Withdrawn
- 2004-02-05 JP JP2006503391A patent/JP2006518383A/ja active Pending
- 2004-02-05 US US10/545,053 patent/US20060074061A1/en not_active Abandoned
- 2004-02-05 US US10/772,963 patent/US20040167109A1/en not_active Abandoned
- 2004-02-05 KR KR1020057015189A patent/KR20050102653A/ko not_active Withdrawn
- 2004-02-19 UY UY28203A patent/UY28203A1/es not_active Application Discontinuation
- 2004-02-19 TW TW093104085A patent/TW200507858A/zh unknown
- 2004-02-20 AR ARP040100545A patent/AR043252A1/es not_active Application Discontinuation
-
2006
- 2006-12-01 JP JP2006326249A patent/JP2007056041A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| UY28203A1 (es) | 2004-08-31 |
| JP2007056041A (ja) | 2007-03-08 |
| US20060074061A1 (en) | 2006-04-06 |
| CN1750829A (zh) | 2006-03-22 |
| AR043252A1 (es) | 2005-07-20 |
| EP1594511A2 (en) | 2005-11-16 |
| PL378209A1 (pl) | 2006-03-20 |
| AU2004212900A1 (en) | 2004-09-02 |
| ZA200505990B (en) | 2006-12-27 |
| CA2516790A1 (en) | 2004-09-02 |
| WO2004073608A2 (en) | 2004-09-02 |
| MXPA05008396A (es) | 2006-03-30 |
| TW200507858A (en) | 2005-03-01 |
| WO2004073608A3 (en) | 2005-03-24 |
| US20040167109A1 (en) | 2004-08-26 |
| BRPI0407742A (pt) | 2006-02-14 |
| CN100431544C (zh) | 2008-11-12 |
| JP2006518383A (ja) | 2006-08-10 |
| KR20050102653A (ko) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6576650B1 (en) | Peripherally active anti-hyperalgesic opiates | |
| US6573282B1 (en) | Peripherally active anti-hyperalgesic opiates | |
| CA2502437A1 (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| RU2010110544A (ru) | Применение веществ для лечения потери зрения у людей с глаукомой и другими дегенеративными глазными заболеваниями | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| RU2004111596A (ru) | Офтальмические композиции в форме депо для периокулярного или субконъюнктивального введения | |
| JP2003505422A5 (https=) | ||
| WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| Caccia | Clonazepam in facial neuralgia and cluster headache: clinical and electrophysiological study | |
| RU2005129278A (ru) | Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз | |
| CA2454976A1 (en) | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient | |
| RU2431502C2 (ru) | Фармацевтические композиции для лечения сухости глаз | |
| WO2019195761A3 (en) | Pharmacological agents for treating ocular diseases | |
| BRPI0414699A (pt) | formulações de acetato de anecortave e acetonida de triancinolona para injeção | |
| DE69534620D1 (de) | Verfahren zur behandlung von augenerkrankungen | |
| JP2006518383A5 (https=) | ||
| WO1995034302A3 (en) | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators | |
| RU2000101091A (ru) | Способ лечения дистрофических заболеваний сетчатки и зрительного нерва | |
| ATE321553T1 (de) | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie | |
| RU94046058A (ru) | Агент для лечения и профилактики катаракты, способ его получения, применение (+) - (2s, 3s)-3 (s)-3-метил-1-(3-метилбутилкарбомоил)бутилкарбамоил]-2-оксикарбоновой кислоты ее соли и ее этилового эфира для получения агента, способ лечения и профилактики катаракты, способ получения водного раствора | |
| RU95106983A (ru) | Офтальмологический состав, способ его получения и средство для офтальмологического состава | |
| RU2006101150A (ru) | Композиции нестероидных противовоспалительных средств для лечения патологического ангиогенеза глаз | |
| CA2442296A1 (en) | Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients | |
| Lean et al. | Infection following retinal detachment surgery. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080910 |